MedTrace Logo

Study on Cefotaxime and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection

NCT01426191 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2032

Last updated 2019-10-04

Study results available
· View outcomes & findings →

Summary

In the proposed study, the investigators plan to evaluate the efficacy and safety of Cefotaxime sodium and sulbactam sodium for injection (2:1)for the treatment of respiratory and urinary tract acute bacterial infection under the widely used in clinical conditions.

Conditions

Interventions

DRUG

xinzhijun

durg:Cefotaxime sodium and sulbactam sodium for injection(2:1) 1.5-3.0g,iv,bid or tid for 5-12 days; Serious infections:1.0-1.5g,iv,tid or qid for 5-12 days

Sponsors & Collaborators

  • Xiangbei Welman Pharmaceutical Co., Ltd

    lead INDUSTRY

Principal Investigators

  • lanjuan lj li, docter · Zhejiang University

  • changqing cq li, doctor · Chongqing Red Cross Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2015-04-30
Completion
2016-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01426191 on ClinicalTrials.gov